PROFILE Trial: Early Treatment with Infliximab, Better Outcomes

N Noor, M Sharip, H Zheng et al. The Lancet Gastroenterology & Hepatology, 2026; 11, 960-970. Open Access! Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn’s disease: 5-year follow-up of the PROFILE trial

Methods: “PROFILE was a multicentre, open-label, randomised controlled trial completed in 40 hospitals in the UK, which included patients aged 16–80 years with newly diagnosed Crohn’s disease. Eligible patients were randomly assigned via a secure online platform to a top-down (infliximab plus immunomodulator) or a step-up protocolised treatment strategy for 48 weeks, after which participants reverted to local standards of care.” 389 patients were enrolled and randomly assigned: 193 to top-down treatment and 193 to step-up treatment. Median follow-up was approximately 5 years from randomization.

Key findings:

  • Crohn’s disease-related abdominal surgeries: 28 in step-up cohort vs 6 in top-down cohort. Time to surgery was shorter in the step-up group than the top-down group (adjusted hazard ratio [aHR] 5·23; p=0·0008)
  • Crohn’s disease-related hospital admissions: 41 (21%) in step-up cohort vs 22 (11%) in top-down cohort
  • Progression to B2 or B3 complications: 32 (17%) in step-up cohort vs 13 (7%) of top-down cohort
  • There was no difference in safety outcomes between the groups for serious infections or malignancy
The dashed vertical line indicates the primary 48-week duration of the PROFILE trial.
The shaded area indicates 95% CI.

My take (borrowed in part from the authors): For many years, early advanced therapy for Crohn’s disease has been common practice by pediatric gastroenterologists. This study shows how important this is. “The failure of even accelerated step-up treatment to catch up to the outcomes of early top-down treatment indicates that delaying effective intervention—if only by months—might allow irreversible damage to accrue and progression to complications that require surgery.”

Related blog posts:

Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept, or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence, or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by the prescribing physician. Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure. This content is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.